MCID: MCP006
MIFTS: 47

Mucoepidermoid Carcinoma

Categories: Rare diseases, Cancer diseases, Oral diseases, Gastrointestinal diseases

Aliases & Classifications for Mucoepidermoid Carcinoma

MalaCards integrated aliases for Mucoepidermoid Carcinoma:

Name: Mucoepidermoid Carcinoma 12 50 14 69
Carcinoma, Mucoepidermoid 42
Carcinoma Mucoepidermoid 52
Mec 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4531
MeSH 42 D018277
NCIt 47 C3772
SNOMED-CT 64 4079000
UMLS 69 C0206694

Summaries for Mucoepidermoid Carcinoma

NIH Rare Diseases : 50 mucoepidermoid carcinoma is a type of cancer of the salivary glands.  salivary gland cancer is diagnosed in 2-3 individuals per 100,000 people each year, and 30-35% of these are mucoepidermoid carcinomas.   mucoepidermoid carcinoma develops when a cell randomly acquires changes (mutations) in genes that regulate how the cell divides such that it begins to grow quickly, forming a cluster of cells (a mass or lump).  the earliest signs of a mucoepidermoid carcinoma may include a lump in the face, neck, or mouth; numbness, weakness, or pain in part of the face; or difficulty swallowing.  treatment often begins with surgery to remove the entire tumor.  in some cases, radiation therapy and/or chemotherapy may be used after surgery to ensure that no cancer cells remain in the body. last updated: 6/18/2013

MalaCards based summary : Mucoepidermoid Carcinoma, also known as carcinoma, mucoepidermoid, is related to laryngeal mucoepidermoid carcinoma and bile duct mucoepidermoid carcinoma. An important gene associated with Mucoepidermoid Carcinoma is CRTC1 (CREB Regulated Transcription Coactivator 1), and among its related pathways/superpathways are Development ERBB-family signaling and CLEC7A (Dectin-1) signaling. The drugs Emend and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, thyroid and lung, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Disease Ontology : 12 A salivary gland carcinoma that is characterized by squamous cells, mucus-secreting cells, and intermediate cells.

Wikipedia : 72 Mucoepidermoid carcinoma is the most common type of salivary gland malignancy in adults. Mucoepidermoid... more...

Related Diseases for Mucoepidermoid Carcinoma

Diseases related to Mucoepidermoid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 243)
id Related Disease Score Top Affiliating Genes
1 laryngeal mucoepidermoid carcinoma 34.5 CRTC1 MAML2
2 bile duct mucoepidermoid carcinoma 33.1 CEACAM5 MUC1 MUC5AC
3 lacrimal gland mucoepidermoid carcinoma 32.3 CEACAM5 EGFR ERBB2 KRT14 MUC5AC
4 mucoepidermoid esophageal carcinoma 29.7 CEACAM5 KRT7 MUC1 MUC2 MUC4 MUC5AC
5 gastric adenocarcinoma 29.2 MKI67 PCNA
6 lung cancer 27.3 AREG CEACAM5 EGFR ERBB2 KRT7 MUC4
7 sclerosing mucoepidermoid carcinoma with eosinophilia 12.3
8 cutaneous mucoepidermoid carcinoma 12.1
9 lung mucoepidermoid carcinoma 12.0
10 breast mucoepidermoid carcinoma 11.9
11 thymus mucoepidermoid carcinoma 11.9
12 bronchus mucoepidermoid carcinoma 11.8
13 trachea mucoepidermoid carcinoma 11.8
14 paranasal sinus cancer 11.0
15 fallopian tube transitional cell carcinoma 10.9 CRTC1 MAML2
16 infiltrating ureter transitional cell carcinoma 10.9 EGFR ERBB2
17 rete testis neoplasm 10.8 CRTC1 EGFR MAML2
18 pancreatic serous cystadenoma 10.8 CRTC1 MAML2 MUC1
19 childhood mediastinal neurogenic tumor 10.8 CALCA TG
20 bladder tuberculosis 10.8 ERBB2 TG
21 myeloid/lymphoid neoplasm associated with pdgfra rearrangement 10.8 EGFR MUC1
22 eccrine papillary adenoma 10.8 CRTC1 MAML2
23 her2-receptor negative breast cancer 10.8 EGFR ERBB2
24 subglottis verrucous carcinoma 10.7 EGFR ERBB2 MUC1
25 corneal ectasia 10.7 CALCA TG
26 pediatric infratentorial ependymoma 10.7 EGFR MKI67
27 cervical endometrial stromal sarcoma 10.7 CALCA TG
28 situs inversus 10.7 MUC1 MUC2
29 situs inversus totalis with cystic dysplasia of kidneys and pancreas 10.6 MKI67 MUC1
30 comedo carcinoma 10.6 EGFR ERBB2 KRT14
31 x-linked intellectual disability, porteous type 10.6 CALCA ERBB2 TP63
32 ductal carcinoma in situ 10.6 EGFR ERBB2 KRT14
33 urinary system disease 10.6 MUC1 MUC2
34 rhinosporidiosis 10.6 KRT13 MUC1
35 anaerobic pneumonia 10.6 EGFR ERBB2 KRT14
36 lung squamous cell carcinoma 10.6 CEACAM5 MUC1
37 measles 10.6 CRTC1 EGFR ERBB2 MAML2
38 cecum adenocarcinoma 10.6 EGFR MUC1 MUC2
39 middle ear squamous cell carcinoma 10.5 EGFR KRT13 KRT14
40 advanced sleep phase syndrome 10.5 MUC1 MUC2 MUC4
41 breast signet ring cell adenocarcinoma 10.5 EGFR ERBB2 MUC2
42 sebaceous adenocarcinoma 10.5 EGFR MUC1 MUC4 TP63
43 ureter squamous cell carcinoma 10.5 CEACAM5 ERBB2
44 struma ovarii 10.5 MUC1 MUC2 MUC4
45 epidermolysa bullosa simplex with muscular dystrophy 10.5 EGFR MKI67 MUC1
46 amelogenesis imperfecta local hypoplastic 10.5 KRT14 MKI67 TP63
47 spleen angiosarcoma 10.5 ACTC1 MUC1
48 bone giant cell tumor 10.5 KRT7 TP63
49 myoma 10.5 ACTC1 MUC1
50 childhood type dermatomyositis 10.5 EGFR MKI67 TP63

Graphical network of the top 20 diseases related to Mucoepidermoid Carcinoma:



Diseases related to Mucoepidermoid Carcinoma

Symptoms & Phenotypes for Mucoepidermoid Carcinoma

MGI Mouse Phenotypes related to Mucoepidermoid Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.61 AREG CRTC1 EGFR ERBB2 KRT14 MUC2
2 homeostasis/metabolism MP:0005376 9.4 EGFR ERBB2 KRT14 KRT7 MUC2 MUC5AC

Drugs & Therapeutics for Mucoepidermoid Carcinoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Emend 17 46 APREPITANT FOSAPREPITANT DIMEGLUMINE Merck March 2003

Drugs for Mucoepidermoid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Doxepin Approved Phase 3 1668-19-5 667477 667468
3
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
4
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
5
Fluconazole Approved Phase 2, Phase 3 86386-73-4 3365
6
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
7
Megestrol acetate Approved, Vet_approved Phase 3 595-33-5 11683
8 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
9
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
10 Liver Extracts Phase 3,Phase 2,Phase 1
11 Anti-Infective Agents Phase 2, Phase 3,Phase 1
12 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
13 Antimitotic Agents Phase 3,Phase 1,Phase 2
14 Adjuvants, Anesthesia Phase 3
15 Analgesics Phase 3
16 Analgesics, Opioid Phase 3
17 Anesthetics Phase 3
18 Anesthetics, General Phase 3
19 Anesthetics, Intravenous Phase 3
20 Central Nervous System Depressants Phase 3
21 Narcotics Phase 3
22 Peripheral Nervous System Agents Phase 3
23 Antidepressive Agents Phase 3
24 Antidepressive Agents, Tricyclic Phase 3
25 Histamine Antagonists Phase 3
26
Histamine Phosphate Phase 3 51-74-1 65513
27 Neurotransmitter Agents Phase 3
28 Psychotropic Drugs Phase 3
29 Autonomic Agents Phase 3
30 Cholinergic Agents Phase 3
31 Antifungal Agents Phase 2, Phase 3,Phase 1
32 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
33 Hormone Antagonists Phase 2, Phase 3
34 Hormones Phase 2, Phase 3,Phase 1
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
36 Steroid Synthesis Inhibitors Phase 2, Phase 3
37 Antineoplastic Agents, Hormonal Phase 3
38 Appetite Stimulants Phase 3
39 Central Nervous System Stimulants Phase 3
40 Contraceptive Agents Phase 3
41 Contraceptives, Oral Phase 3
42
Megestrol Phase 3 3562-63-8 19090 3080587
43 Cola Nutraceutical Phase 3,Phase 2,Phase 1
44
Amifostine Approved, Investigational Phase 1, Phase 2 20537-88-6 2141
45
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
46
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
47
Indinavir Approved Phase 2 150378-17-9 5362440
48
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
49
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
50
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3

Interventional clinical trials:

(show top 50) (show all 78)

id Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
3 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
4 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
5 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
6 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
7 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
8 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
9 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
10 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
11 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
12 Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer Completed NCT00002632 Phase 2 paclitaxel
13 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
14 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
15 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed NCT00095563 Phase 2 lapatinib ditosylate
16 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
17 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
18 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
19 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
20 Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer Completed NCT00004163 Phase 2 Trastuzumab
21 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
22 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
23 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
24 Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
25 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2 cisplatin;paclitaxel
26 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
27 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
28 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery Recruiting NCT01220583 Phase 2 cisplatin
29 Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors Active, not recruiting NCT00859937 Phase 2 dasatinib
30 Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy Active, not recruiting NCT01586767 Phase 2
31 Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer Terminated NCT00126607 Phase 2
32 Title XELOX FOR SALIVARY GLAND CANCERS Terminated NCT00101075 Phase 2 Capecitabine;Oxaliplatin
33 MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer Unknown status NCT00984074 Phase 1
34 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
35 Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
36 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1 alvespimycin hydrochloride
37 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
38 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
39 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
40 Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Completed NCT01637194 Phase 1 everolimus
41 Head & Neck Cancer Survivorship: Physical and Functional Status Completed NCT00751816 Phase 1 systemic chemotherapy
42 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1 tanespimycin
43 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
44 Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed NCT00010023 Phase 1 capecitabine;cisplatin
45 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1 vorinostat
46 Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Completed NCT00019110 Phase 1
47 Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors Completed NCT00006036 Phase 1 cisplatin;lurtotecan liposome
48 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1 docetaxel
49 Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Completed NCT01172028 Phase 1 Taxotere (Docetaxel);Alimta (Pemetrexed)
50 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride

Search NIH Clinical Center for Mucoepidermoid Carcinoma

Cochrane evidence based reviews: carcinoma, mucoepidermoid

Genetic Tests for Mucoepidermoid Carcinoma

Anatomical Context for Mucoepidermoid Carcinoma

MalaCards organs/tissues related to Mucoepidermoid Carcinoma:

39
Salivary Gland, Thyroid, Lung, Brain, Liver, Breast, Skin

Publications for Mucoepidermoid Carcinoma

Articles related to Mucoepidermoid Carcinoma:

(show top 50) (show all 683)
id Title Authors Year
1
Perineural Spread of Mucoepidermoid Carcinoma of Parotid Gland Involving V, VI, and VII Cranial Nerves Demonstrated on Positron Emission Tomography/Computed Tomography. ( 28680219 )
2017
2
Prognostic factors and occult nodal disease in mucoepidermoid carcinoma of the oral cavity and oropharynx: An analysis of the National Cancer Database. ( 28797455 )
2017
3
Intraosseous mucoepidermoid carcinoma: Outcome review. ( 28833169 )
2017
4
Mucoepidermoid Carcinoma in the Skull of an Orange-winged Amazon Parrot (Amazona amazonica). ( 28891704 )
2017
5
Warthin Tumor-Like Mucoepidermoid Carcinoma. ( 28793830 )
2017
6
Contrast-enhanced endoscopic ultrasonography features of a mucoepidermoid carcinoma of the pancreas. ( 28836518 )
2017
7
Dermoscopic features of mucoepidermoid carcinoma of the lip. ( 28593658 )
2017
8
Cytological features of the Warthin-like variant of salivary mucoepidermoid carcinoma. ( 28755513 )
2017
9
Nasal cavity tumefactive fibroinflammatory lesion mimicking recurrent mucoepidermoid carcinoma. ( 28846782 )
2017
10
Case Report: Recurrent Mucoepidermoid Carcinoma of the Tongue in Adult Female Patient With Lung Cancer. ( 28757800 )
2017
11
A Rare Cause of Duodenal Obstruction: Metastatic Parotid Mucoepidermoid Carcinoma. ( 28351791 )
2017
12
Sclerosing Mucoepidermoid Carcinoma of the Submandibular Gland Presenting as Chronic Sialadenitis: A Case Report and Review of Literature. ( 28516348 )
2017
13
Mucoepidermoid carcinoma of the sublingual gland harboring a translocation of the MAML2 gene: A case report. ( 28927048 )
2017
14
Mucoepidermoid Carcinoma of Salivary Gland: Limitations and Pitfalls on FNA. ( 28658793 )
2017
15
18F-FDG PET/CT Imaging of Tracheal Mucoepidermoid Carcinoma. ( 28872555 )
2017
16
Mucoepidermoid carcinoma-associated expression of MUC5AC, MUC5B and mucin-type carbohydrate antigen sialyl-Tn in the parotid gland. ( 28628803 )
2017
17
Fluorine-18-fluorodeoxyglucose positron emission tomography/ computed tomography findings in a pediatric mucoepidermoid carcinoma and differential diagnosis. ( 28697196 )
2017
18
Spindle Cell Mucoepidermoid Carcinoma of the Palatine Tonsil With CRTC1-MAML2 Fusion Transcript: Report of a Rare Case in a 17-Year-Old Boy and a Review of the Literature. ( 28637362 )
2017
19
MAML2 Rearrangements in Variant Forms of Mucoepidermoid Carcinoma: Ancillary Diagnostic Testing for the Ciliated and Warthin-like Variants. ( 28877061 )
2017
20
Primary mucoepidermoid carcinoma of the lung with prominent clear cells. ( 28670072 )
2017
21
Immunohistochemical expression profiles of mucin antigens in salivary gland mucoepidermoid carcinoma: MUC4- and MUC6-negative expression predicts a shortened survival in the early postoperative phase. ( 28649694 )
2017
22
Bulbar conjunctival metastasis from mucoepidermoid carcinoma of parotid-a case report and review of literature. ( 28061862 )
2017
23
Immunohistochemical investigations on the expression of programmed cell death ligand 1, human leukocyte antigens G and E, and granzyme B in intraoral mucoepidermoid carcinoma. ( 28711734 )
2017
24
Expression of Membrane-Bound Mucins and p63 in Distinguishing Mucoepidermoid Carcinoma from Papillary Cystadenoma. ( 27278378 )
2016
25
Cutaneous Metastasis of a Mucoepidermoid Carcinoma of the Pancreas: First Reported Case. ( 27043340 )
2016
26
SOX10-positive salivary gland tumors: a growing list, including mammary analogue secretory carcinoma of the salivary gland, sialoblastoma, low-grade salivary duct carcinoma, basal cell adenoma/adenocarcinoma, and a subgroup of mucoepidermoid carcinoma. ( 27327192 )
2016
27
Paediatric mucoepidermoid carcinoma. ( 26976338 )
2016
28
Primary Mucoepidermoid Carcinoma of the Lacrimal Sac -a88 a Case Report and Literature Review. ( 27534787 )
2016
29
Diagnostic and prognostic utility of Mastermind-like 2 (MAML2) gene rearrangement detection by fluorescent in situ hybridization (FISH) in mucoepidermoid carcinoma of the salivary glands. ( 27068311 )
2016
30
Central mucoepidermoid carcinoma radiographically mimicking an odontogenic tumor: A case report and literature review. ( 27721620 )
2016
31
Case of parotid mucoepidermoid carcinoma: Expanding the spectrum of von Hippel-Lindau-related neoplasms. ( 28006088 )
2016
32
MAML2 Status in Mucoepidermoid Carcinoma Can No Longer Be Considered a Prognostic Marker. ( 27299797 )
2016
33
The use of immunohistochemistry in detection of perineural invasion in mucoepidermoid carcinoma. ( 27068680 )
2016
34
Surgery combined with postoperative (125) I seed brachytherapy for the treatment of mucoepidermoid carcinoma of the parotid gland in pediatric patients. ( 27576792 )
2016
35
Mucoepidermoid carcinoma of the trachea. ( 27773119 )
2016
36
Re-evaluation of MAML2 fusion-negative mucoepidermoid carcinoma: a subgroup being actually hyalinizing clear cell carcinoma of the salivary gland with EWSR1 translocation. ( 27769871 )
2016
37
Massive hemoptysis due to primary mucoepidermoid carcinoma of the lung in a 12-year-old. ( 27216748 )
2016
38
Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma. ( 27340278 )
2016
39
Thyroid sclerosing mucoepidermoid carcinoma with eosinophilia: a clinicopathologic and molecular analysis of a distinct entity. ( 27910944 )
2016
40
Mucoepidermoid Carcinoma - Unknown Primary Affecting the Neck. ( 27272843 )
2016
41
Parotid sclerosing mucoepidermoid carcinoma: a case report and immunohistochemical study. ( 28002531 )
2016
42
The oncofetal protein IMP3 is an indicator of early recurrence and poor outcome in mucoepidermoid carcinoma of salivary glands. ( 27458536 )
2016
43
Twist Expression in Pleomorphic Adenoma, Adenoid Cystic Carcinoma and Mucoepidermoid Carcinoma of Salivary Glands. ( 26832177 )
2016
44
CRTC1-MAML2 gene fusion in G-CSF-secreting mucoepidermoid carcinoma: an indicator of favourable prognosis? ( 27101634 )
2016
45
Endoscopic Endonasal Resection of Recurrent Nasopharyngeal Mucoepidermoid Carcinoma. ( 27171943 )
2016
46
Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid: A cytological dilemma. ( 27011441 )
2016
47
Oncocytic mucoepidermoid carcinoma: A case report and review of literature. ( 27773121 )
2016
48
Sclerosing Mucoepidermoid Carcinoma of the Parotid Gland. ( 27602340 )
2016
49
Secondary mucoepidermoid carcinoma of the orbit. ( 27146939 )
2016
50
Mucoepidermoid carcinoma arising in Warthin's tumor of the parotid gland: Clinicopathological characteristics and immunophenotypes. ( 27417276 )
2016

Variations for Mucoepidermoid Carcinoma

Cosmic variations for Mucoepidermoid Carcinoma:

9 (show all 40)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM43680 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.523C>T p.R175C 15
2 COSM43797 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.550G>C p.D184H 15
3 COSM46282 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.501G>C p.Q167H 15
4 COSM44853 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.661G>A p.E221K 15
5 COSM44850 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.494A>T p.Q165L 15
6 COSM46283 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.569C>A p.P190H 15
7 COSM44119 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.483C>T p.A161A 15
8 COSM1389051 SMAD4 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.993G>A p.M331I 15
9 COSM5069 PTEN salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.760A>G p.K254E 15
10 COSM546 KRAS salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.175G>A p.A59T 15
11 COSM483 HRAS salivary gland,mouth floor,carcinoma,mucoepidermoid carcinoma c.35G>T p.G12V 15
12 COSM491 HRAS salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.39T>A p.G13G 15
13 COSM484 HRAS salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.35G>A p.G12D 15
14 COSM1659071 WASF2 salivary gland,mouth,carcinoma,NS c.15G>T p.T5T 12
15 COSM1659031 TRPV5 salivary gland,mouth,carcinoma,NS c.554A>G p.H185R 12
16 COSM1658989 TP53BP1 salivary gland,mouth,carcinoma,NS c.3854C>G p.T1285S 12
17 COSM1659046 THRA salivary gland,mouth,carcinoma,NS c.1162C>T p.R388W 12
18 COSM1658912 SLC26A2 salivary gland,mouth,carcinoma,NS c.1474C>T p.R492W 12
19 COSM1659033 RNF38 salivary gland,mouth,carcinoma,NS c.623A>G p.H208R 12
20 COSM1659036 MELK salivary gland,mouth,carcinoma,NS c.817T>C p.W273R 12
21 COSM1659003 MAP2 salivary gland,mouth,carcinoma,NS c.31G>T p.A11S 12
22 COSM51382 KRAS salivary gland,mouth,carcinoma,NS c.50G>A p.S17N 12
23 COSM51381 KIT salivary gland,face,carcinoma,NS c.2386A>G p.R796G 12
24 COSM1658780 KDM6A salivary gland,mouth,carcinoma,NS c.2833-1G>A p.? 12
25 COSM1658957 HNRNPDL salivary gland,mouth,carcinoma,NS c.289C>T p.R97C 12
26 COSM1658892 HK1 salivary gland,mouth,carcinoma,NS c.370C>G p.H124D 12
27 COSM1659047 HECTD4 salivary gland,mouth,carcinoma,NS c.6707G>A p.S2236N 12
28 COSM1658983 GTF3C3 salivary gland,mouth,carcinoma,NS c.2602C>G p.Q868E 12
29 COSM1658965 DYRK4 salivary gland,mouth,carcinoma,NS c.1733G>A p.R578H 12
30 COSM1658899 COL22A1 salivary gland,mouth,carcinoma,NS c.4115G>C p.G1372A 12
31 COSM1658935 CHEK2 salivary gland,mouth,carcinoma,NS c.508G>A p.V170I 12
32 COSM1658880 CDAN1 salivary gland,mouth,carcinoma,NS c.2248G>T p.G750C 12
33 COSM51383 BRAF salivary gland,mouth,carcinoma,NS c.1768G>A p.V590I 12
34 COSM34223 AXL salivary gland,mouth,carcinoma,NS c.1522G>A p.G508S 12
35 COSM1658913 salivary gland,mouth,carcinoma,NS c.1657G>A p.G553R 12
36 COSM1658893 salivary gland,mouth,carcinoma,NS c.358C>G p.H120D 12
37 COSM1658951 salivary gland,mouth,carcinoma,NS c.236G>A p.R79H 12
38 COSM1658894 salivary gland,mouth,carcinoma,NS c.355C>G p.H119D 12
39 COSM1659048 salivary gland,mouth,carcinoma,NS c.7457G>A p.S2486N 12
40 COSM1659004 salivary gland,mouth,carcinoma,NS c.31G>T p.A11S 12

Expression for Mucoepidermoid Carcinoma

Search GEO for disease gene expression data for Mucoepidermoid Carcinoma.

Pathways for Mucoepidermoid Carcinoma

GO Terms for Mucoepidermoid Carcinoma

Cellular components related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 ACTC1 AREG CALCA EGFR MUC1 MUC4
2 Golgi lumen GO:0005796 8.92 MUC1 MUC2 MUC4 MUC5AC
3 nucleus GO:0005634 10 AREG CALCA CRTC1 CRTC3 EGFR ERBB2

Biological processes related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.72 AREG EGFR ERBB2 MKI67 PCNA
2 protein homotetramerization GO:0051289 9.54 CRTC1 CRTC3 TP63
3 response to lipid GO:0033993 9.48 EGFR PCNA
4 positive regulation of CREB transcription factor activity GO:0032793 9.46 CRTC1 CRTC3
5 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.46 MUC1 MUC2 MUC4 MUC5AC
6 negative regulation of ERBB signaling pathway GO:1901185 9.43 EGFR ERBB2
7 positive regulation of DNA replication GO:0045740 9.43 AREG EGFR PCNA
8 maintenance of gastrointestinal epithelium GO:0030277 9.4 MUC2 MUC4
9 epithelial cell differentiation GO:0030855 9.26 KRT14 MUC1 PCNA TP63
10 O-glycan processing GO:0016266 8.92 MUC1 MUC2 MUC4 MUC5AC

Molecular functions related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 CALCA CEACAM5 EGFR ERBB2 PCNA TP63
2 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.96 EGFR ERBB2
3 cAMP response element binding protein binding GO:0008140 8.62 CRTC1 CRTC3

Sources for Mucoepidermoid Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....